These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25731444)

  • 1. [A case of advanced hepatocellular carcinoma successfully treated by liver resection after complete response induced by sorafenib administration].
    Kim Y; Hosoda Y; Kakita N; Yamada Y; Yamasaki M; Nishino M; Okano M; Nagai K; Yasui M; Tsujinaka T
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2124-6. PubMed ID: 25731444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.
    Nakamura K; Beppu T; Hayashi H; Okabe H; Imai K; Nitta H; Chikamoto A; Ishiko T; Sasaki M; Baba H
    Int Surg; 2015 May; 100(5):908-14. PubMed ID: 26011214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.
    Kitajima T; Hatano E; Mitsunori Y; Taura K; Fujimoto Y; Mizumoto M; Okajima H; Kaido T; Minamiguchi S; Uemoto S
    Clin J Gastroenterol; 2015 Oct; 8(5):300-5. PubMed ID: 26249525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
    Wang W; Bai W; Wang E; Zhao Y; Liu L; Yang M; Cai H; Xia D; Zhang L; Niu J; Yin Z; Zhang Z; Fan D; Xia J; Han G
    Int J Cancer; 2017 Jan; 140(2):390-399. PubMed ID: 27681592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Three cases of recurrent hepatocellular carcinoma treated with laparoscopic hepatectomy after oral administration of sorafenib].
    Komatsu H; Tsukamoto T; Kodai S; Kanazawa A; Shimizu S; Yamazoe S; Ohira G; Nakajima T; Nakai T; Kawasaki Y; Kioka K
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1672-4. PubMed ID: 24393884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A Case of Advanced Hepatocellular Carcinoma Successfully Treated with Liver Resection after Administration of Sorafenib].
    Kodai S; Kanazawa A; Kinoshita M; Hamano G; Nishio K; Murata A; Shimizu S; Kikuchi T; Yonemitsu K; Shirai D; Nobori C; Tashima T; Goto W; Miura K; Maeda K
    Gan To Kagaku Ryoho; 2020 Mar; 47(3):502-504. PubMed ID: 32381929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy.
    Yoshimoto T; Imura S; Morine Y; Ikemoto T; Arakawa Y; Iwahashi S; Saito YU; Takasu C; Ishikawa D; Teraoku H; Bando Y; Shimada M
    Anticancer Res; 2018 Jan; 38(1):501-507. PubMed ID: 29277815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma.
    Maida M; Macaluso FS; Valenza F; Virdone R
    J Gastrointestin Liver Dis; 2016 Jun; 25(2):253-5. PubMed ID: 27308660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
    Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Complete Surgical Resection of a Huge Hepatocellular Carcinoma Invading the Diaphragm and Lung after Transcatheter Arterial Chemoembolization (TACE) and Sorafenib--A Case Report].
    Mukai Y; Wada H; Eguchi H; Tomokuni A; Tomimaru Y; Asaoka T; Kawamoto K; Marubashi S; Umeshita K; Doki Y; Mori M; Nagano H
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1638-40. PubMed ID: 26805122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
    Park JG
    Clin Mol Hepatol; 2015 Sep; 21(3):287-94. PubMed ID: 26527250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
    J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
    Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
    Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of Sorafenib for Extrahepatic Recurrence of Hepatocellular Carcinoma after Liver Resection].
    Yokoo H; Kamiyama T; Kakisaka T; Orimo T; Wakayama K; Shimada S; Tsuruga Y; Kamachi H; Taketomi A
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1497-9. PubMed ID: 26805075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib.
    Liu D; Liu A; Peng J; Hu Y; Feng X
    Eur J Med Res; 2015 Feb; 20(1):12. PubMed ID: 25649133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy].
    Mukai R; Wada H; Tomimaru Y; Hama N; Kawamoto K; Kobayashi S; Eguchi H; Umeshita K; Doki Y; Mori M; Nagano H
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1813-5. PubMed ID: 24393931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Two Patients with Recurrence of Hepatocellular Carcinoma after Liver Resection Who Achieved Long-Term Stable Disease with Small Doses of Sorafenib Therapy].
    Kitade H; Yanagida H; Yokoigawa N; Yamada M; Hijikawa T; Kaibori M; Matsui K; Ishizaki M; Yoshioka K; Kon M
    Gan To Kagaku Ryoho; 2015 Jul; 42(7):863-5. PubMed ID: 26197751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.
    Kaufmann S; Thaiss WM; Schulze M; Bitzer M; Lauer U; Nikolaou K; Horger M
    Acta Radiol; 2018 Jul; 59(7):765-772. PubMed ID: 28927298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.